Harnessing natural killer T cells to advance cancer immunotherapy for solid tumors
In the fight against cancer, chimeric antigen receptor (CAR) T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. A study demonstrates that a different immunotherapy approach utilizing natural killer T cells produced significant antitumor activity in preclinical models of solid tumors.
In the fight against cancer, chimeric antigen receptor (CAR) T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. A study demonstrates that a different immunotherapy approach utilizing natural killer T cells produced significant antitumor activity in preclinical models of solid tumors.
